fast

Hemophilia Commercial Effectiveness Tracker

With the introduction of new long acting therapies, the hemophilia market is poised for rapid change. This report examines the projected impact of Biogen Idec's new drugs ELOCTATE and ALPROLIX on the hemophilia A and B market respectively.

Report Summary

In the first wave of this report, we examined how hemophilia is currently being treated and the impact that long acting therapies,Biogen Idec's ELOCTATE and ALPROLIX specifically, will have on the US market. Our research indicates that Biogen Idec’s new therapies will play a significant role in the hemophilia A market. Physicians who treat hemophilia see the value that a reduced dosing frequency will have on patients’ quality of life and on treatment compliance.

We interviewed over 150 US-based, hemophilia-treating physicians in June and July of 2013 for this report. Subsequent waves of this report will explore the evolving perception and use of these new therapies, and other key events in the hemophilia market.

Download the report preview to learn more.

Report Content

fast
Current Market Share

Market share by disease severity, patient age groups and treatment types (prophy & episodic).

fast
Attributes & Performance

Performance of current therapies against treatment attributes like bleed rate control and dosing frequency.

fast
Impact of New Therapies

Perceived performance of new therapies and their impact on market share.

fast
Drivers & Barriers

Projected switching behavior across segments and switching drivers and barriers.

fast
Sales Activity

Share of Voice, Message Recall & Counter Messaging.

Report Details

Reports
Specifications
Deliverables
Additional Services
Timeline

  • Hemophilia A

    Two individual reports


    Hemophilia B

  • United States

    150 Physicians

    Quant/Qual (Voice)

  • Report

    Presentation

    Web Dashboard

  • Add proprietary questions to our surveys.


    Conduct your own research using our panel.


    Additional data slices for your unique needs.

  • Subscribe to receive all reports

    Or buy individual reports
    *Additional waves are launched to capture the impact of new market events.

Reports


Hemophilia A

Hemophilia B

Specifications


United States

150 Physicians

Quant/Qual (Voice)

Deliverables


Report

Presentation

Web Dashboard

Additional Services


Add proprietary questions to our surveys.


Conduct your own research using our panel.


Additional data slices for your unique needs.

Timeline

Subscribe to receive all reports.


Or buy individual reports

*Additional waves are launched to capture the impact of new market events.

Contact Us

Submit
Enter your email to know more about Hemophilia commercial effectiveness tracker